Human MT(Melatonin) ELISA Kit (E-EL-H2016)

This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Human MT. During the reaction, Human MT in the sample or standard competes with a fixed amount of Human MT on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Human MT. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Human MT in tested samples can be calculated by comparing the OD of the samples to the standard curve.

Intelectin 1 (ITLN1), also called omentin, is a calcium-dependent galactofuranose-binding lectin of the X-lectin family that contains a fibrinogen-related domain and circulates as a disulfide-linked, N-glycosylated homotrimer. It is secreted by intestinal epithelial cells, including goblet and Paneth cells, and by visceral omental adipose tissue, and its circulating levels are regulated by metabolic status, insulin and the amount of visceral adipose tissue. Intelectin 1 binds galactofuranose-containing glycans of bacteria, fungi and protozoa but not the corresponding human glycans, and thereby participates in mucosal innate antimicrobial defense, pathogen recognition and maintenance of the mucus barrier. As an adipokine, omentin enhances insulin-stimulated glucose uptake and AKT phosphorylation in adipocytes, exerts anti-inflammatory and vasodilatory effects on endothelial cells through endothelial nitric oxide synthase and AMP-activated protein kinase, and its circulating level correlates positively with insulin sensitivity, falling in obesity, type 2 diabetes and metabolic syndrome. Intelectin 1 is also up-regulated in asthmatic airways, where it promotes allergic inflammation and eosinophil recruitment, and altered expression has been reported in inflammatory bowel disease, atherosclerosis and several cancers. Reduced circulating omentin is considered a candidate indicator of insulin resistance, endothelial dysfunction and adverse cardiometabolic risk, and measurement of ITLN1 supports research on innate immunity, adipose tissue biology and obesity-related metabolic disease.